Literature DB >> 27521874

Retroviral vector interactions with hematopoietic cells.

Elizabeth M Everson1, Grant D Trobridge2.   

Abstract

Hematopoietic stem cell (HSC) gene therapy using retroviral vectors is a powerful and promising approach to permanently correct many hematopoietic disorders. Increasing the transduction of quiescent HSCs and reducing genotoxicity are major challenges in the field. Retroviral vectors, including lentiviral and foamy vectors, have been extensively modified resulting in improved safety and efficacy. This review will focus on recent advances to improve vector entry, transduction efficiency, control of transgene expression and approaches to improve safety by modifying the retroviral integration profile. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27521874      PMCID: PMC5138074          DOI: 10.1016/j.coviro.2016.07.010

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  53 in total

1.  Cell cycle requirements for transduction by foamy virus vectors compared to those of oncovirus and lentivirus vectors.

Authors:  Grant Trobridge; David W Russell
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Genomic and functional assays demonstrate reduced gammaretroviral vector genotoxicity associated with use of the cHS4 chromatin insulator.

Authors:  Chang Long Li; Ding Xiong; George Stamatoyannopoulos; David W Emery
Journal:  Mol Ther       Date:  2009-02-24       Impact factor: 11.454

3.  Growth-supporting activities of fibronectin on hematopoietic stem/progenitor cells in vitro and in vivo: structural requirement for fibronectin activities of CS1 and cell-binding domains.

Authors:  T Yokota; K Oritani; H Mitsui; K Aoyama; J Ishikawa; H Sugahara; I Matsumura; S Tsai; Y Tomiyama; Y Kanakura; Y Matsuzawa
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

4.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells.

Authors:  H Hanenberg; X L Xiao; D Dilloo; K Hashino; I Kato; D A Williams
Journal:  Nat Med       Date:  1996-08       Impact factor: 53.440

5.  Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates.

Authors:  Virginie Sandrin; Bertrand Boson; Patrick Salmon; Wilfried Gay; Didier Nègre; Roger Le Grand; Didier Trono; François-Loïc Cosset
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

6.  Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.

Authors:  Eirini P Papapetrou; Damian Kovalovsky; Laurent Beloeil; Derek Sant'angelo; Michel Sadelain
Journal:  J Clin Invest       Date:  2008-12-01       Impact factor: 14.808

7.  Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells.

Authors:  Cathy X Wang; Blythe D Sather; Xuefeng Wang; Jennifer Adair; Iram Khan; Swati Singh; Shanshan Lang; Amie Adams; Gabrielle Curinga; Hans-Peter Kiem; Carol H Miao; David J Rawlings; Bruce E Torbett
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

8.  A genetic strategy for single and combinatorial analysis of miRNA function in mammalian hematopoietic stem cells.

Authors:  Eirini P Papapetrou; James E Korkola; Michel Sadelain
Journal:  Stem Cells       Date:  2010-02       Impact factor: 6.277

9.  Transcription start regions in the human genome are favored targets for MLV integration.

Authors:  Xiaolin Wu; Yuan Li; Bruce Crise; Shawn M Burgess
Journal:  Science       Date:  2003-06-13       Impact factor: 47.728

10.  Integration of murine leukemia virus DNA depends on mitosis.

Authors:  T Roe; T C Reynolds; G Yu; P O Brown
Journal:  EMBO J       Date:  1993-05       Impact factor: 11.598

View more
  1 in total

Review 1.  Evolving Gene Therapy in Primary Immunodeficiency.

Authors:  Adrian J Thrasher; David A Williams
Journal:  Mol Ther       Date:  2017-03-31       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.